JP2025514142A5 - - Google Patents
Info
- Publication number
- JP2025514142A5 JP2025514142A5 JP2024563061A JP2024563061A JP2025514142A5 JP 2025514142 A5 JP2025514142 A5 JP 2025514142A5 JP 2024563061 A JP2024563061 A JP 2024563061A JP 2024563061 A JP2024563061 A JP 2024563061A JP 2025514142 A5 JP2025514142 A5 JP 2025514142A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- amino acid
- acid sequence
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263334381P | 2022-04-25 | 2022-04-25 | |
| US63/334,381 | 2022-04-25 | ||
| US202263374646P | 2022-09-06 | 2022-09-06 | |
| US63/374,646 | 2022-09-06 | ||
| PCT/US2023/066114 WO2023212518A1 (en) | 2022-04-25 | 2023-04-24 | Antibody molecules to april and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514142A JP2025514142A (ja) | 2025-05-02 |
| JP2025514142A5 true JP2025514142A5 (https=) | 2026-05-01 |
Family
ID=86332309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563061A Pending JP2025514142A (ja) | 2022-04-25 | 2023-04-24 | Ａｐｒｉｌに対する抗体分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240092921A1 (https=) |
| EP (1) | EP4514381A1 (https=) |
| JP (1) | JP2025514142A (https=) |
| KR (1) | KR20250018167A (https=) |
| CN (1) | CN119730874A (https=) |
| AU (1) | AU2023262513A1 (https=) |
| CA (1) | CA3256431A1 (https=) |
| TW (1) | TW202400637A (https=) |
| WO (1) | WO2023212518A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| AU2023366516A1 (en) * | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2026050274A2 (en) * | 2024-08-27 | 2026-03-05 | Paragon Therapeutics, Inc. | April binding proteins, compositions, and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US20210340266A1 (en) * | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CA2754127C (en) | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| WO2021243298A1 (en) | 2020-05-29 | 2021-12-02 | Chinook Therapeutics, Inc. | Methods of treating iga nephropathy with an april binding antibody |
| CA3187823A1 (en) * | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Antibody molecules to april and uses thereof |
-
2023
- 2023-04-24 US US18/305,667 patent/US20240092921A1/en active Pending
- 2023-04-24 WO PCT/US2023/066114 patent/WO2023212518A1/en not_active Ceased
- 2023-04-24 EP EP23723396.0A patent/EP4514381A1/en active Pending
- 2023-04-24 KR KR1020247038918A patent/KR20250018167A/ko active Pending
- 2023-04-24 JP JP2024563061A patent/JP2025514142A/ja active Pending
- 2023-04-24 CA CA3256431A patent/CA3256431A1/en active Pending
- 2023-04-24 CN CN202380048107.0A patent/CN119730874A/zh active Pending
- 2023-04-24 AU AU2023262513A patent/AU2023262513A1/en active Pending
- 2023-04-24 TW TW112115157A patent/TW202400637A/zh unknown
-
2024
- 2024-08-23 US US18/814,058 patent/US20250043014A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025514142A5 (https=) | ||
| EP3487883B1 (en) | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 | |
| JP2023548858A5 (https=) | ||
| JP2022512967A (ja) | 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法 | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2013166765A5 (https=) | ||
| RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
| KR102101478B1 (ko) | 자가면역 및 염증성 질환의 치료를 위한 방법 및 조성물 | |
| JP2020079331A (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| JP2024127990A (ja) | アミロイドーシスを処置するための組成物 | |
| Linker et al. | Use of intravenous immunoglobulin and plasma exchange in neurological disease | |
| KR20250016223A (ko) | 항인슐린 수용체 항체를 위한 제형 및 이의 용도 | |
| JP2023531722A5 (https=) | ||
| Elliott et al. | Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases | |
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| CN105017414A (zh) | 偶联重组Pro-A和/或G多糖亲和介质及其应用 | |
| US20200172603A1 (en) | Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients | |
| JP2024539751A (ja) | 抗ｃｄ２２抗体の水性製剤およびそれらの使用 | |
| CN116440263A (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| WO2023025249A1 (zh) | 一种含融合蛋白的药物组合物 | |
| Bujnowska et al. | Outcomes of prolonged treatment with intravenous immunoglobulin infusions for acute antibody-mediated rejection in kidney transplant recipients | |
| Harding | Eculizumab | |
| CN114901313A (zh) | 急性期的视神经脊髓炎的预防或治疗剂 | |
| RU2024134791A (ru) | Молекулы анти-april антитела и их применение |